10x Genomics, Inc. (TXG) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
TXG EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
TXG Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 69.1% | -17.2% | -6.8% |
| 2024 | 67.9% | -31.9% | -29.9% |
| 2023 | 66.2% | -42.9% | -41.2% |
| 2022 | 76.7% | -32.5% | -32.1% |
| 2021 | 84.9% | -10.8% | -11.9% |
Download Data
Export TXG earnings history in CSV or JSON format
Free sign-in required to download data
10x Genomics, Inc. (TXG) Earnings Overview
As of May 8, 2026, 10x Genomics, Inc. (TXG) reported trailing twelve-month net income of -$44M, reflecting +77.0% year-over-year growth. The company earned $-0.34 per diluted share over the past four quarters, with a net profit margin of -6.8%.
Looking at the long-term picture, TXG's historical earnings data spans multiple years. The company achieved its highest annual net income of -$19M in fiscal 2017.
10x Genomics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PACB (-$546M net income, -341.5% margin), ILMN ($853M net income, 19.6% margin), BRKR (-$12M net income, -0.3% margin), TXG has outperformed on profitability metrics. Compare TXG vs PACB →
TXG Earnings vs Peers
Earnings metrics vs comparable public companies
TXG Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$44M | +76.2% | -$111M | $-0.35 | -6.8% | -17.2% |
| 2024 | -$183M | +28.4% | -$195M | $-1.52 | -29.9% | -31.9% |
| 2023 | -$255M | -53.7% | -$265M | $-2.18 | -41.2% | -42.9% |
| 2022 | -$166M | -185.1% | -$168M | $-1.46 | -32.1% | -32.5% |
| 2021 | -$58M | +89.3% | -$53M | $-0.53 | -11.9% | -10.8% |
| 2020 | -$543M | -1636.7% | -$85M | $-5.37 | -181.6% | -28.6% |
| 2019 | -$31M | +72.2% | -$29M | $-0.80 | -12.7% | -11.8% |
| 2018 | -$112M | -499.5% | -$111M | $-8.40 | -76.9% | -75.7% |
| 2017 | -$19M | - | -$18M | $-1.62 | -26.4% | -25.8% |
See TXG's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TXG Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TXG vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTXG — Frequently Asked Questions
Quick answers to the most common questions about buying TXG stock.
Is TXG growing earnings?
TXG EPS is $-0.34, with earnings growth accelerating to +77.0%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-44M.
What are TXG's profit margins?
10x Genomics, Inc. net margin is -6.8%, with operating margin at -17.2%. Below-average margins reflect competitive or cost pressures.
How consistent are TXG's earnings?
TXG earnings data spans 2017-2025. The accelerating earnings trend is +77.0% YoY. Historical data enables comparison across business cycles.